Table 7. Overall Qualitative Summary.
| Survival Relationship | Pathology Relationship | |||||
| Pathway | Michigan | France | Japan | Michigan | France | Japan |
| Cell Cycle (+) | X (poor) | X (poor) | CIS (−); Acinar (+); Pap (−); Solid (+) | CIS (−); Pap (−); Solid (+) | ||
| ESC | ||||||
| B-cell | X (good) | Acinar (−) | ||||
| T-cell | ||||||
| Antigen | X(good) | |||||
| AKT/PI3K | X (poor) | X (poor) | Pap (−) | Acinar (+); Solid (−) | ||
| IGF-1 | X (good) | Acinar (+); Pap (−) | Acinar (+); Pap (+) | |||
| Chemokine | ||||||
| NF-κB | ||||||
| Notch | X (poor) | Pap (+); Solid (−) | Acinar (+) | |||
| JAK/STAT | X (poor) | |||||
| Complement | X (good) | Acinar (+); Solid (−) | Pap (+); Solid (−) | |||
| mTOR | X (poor) | X (poor) | Acinar (−) | Solid (+) | ||
| Cell Cycle (−) | X (good) | Acinar (−) | Acinar (+); Pap (−) | |||
| Angiogenesis | X (poor) | Acinar (−); Pap (−); Solid (+) | CIS (+); Acinar (−) | CIS (−) | ||
| IL-stimulatory | X (poor) | CIS (−) | CIS (−); Acinar (+); Pap (+); Solid (−) | Acinar (−) | ||
| IL-suppressive | X (poor) | |||||
| Interferon | X (good) | Pap (+) | ||||
| EGFR | X (good) | Acinar (−); Pap (+) | Pap (+) | |||
| PDGF | X (poor) | Acinar (+) | Acinar (+) | CIS (+); Pap (−); Solid (+) | ||
| Hypoxia | X (poor) | Pap (+) | Acinar (+) | |||
| PTEN | ||||||
| Pro-apoptosis | X (good) | CIS (−) | ||||
| Anti-apoptosis | Solid (+) | |||||
| TGF-β | Pap (−); Solid (+) | |||||
| Hedgehog | X (poor) | Pap (+); Solid (−) | ||||
| Wnt | Solid (−) | Acinar (+); Solid (−) | Solid (−) | |||
An overall qualitative summary. Items in italics indicate validation in two or three of the three datasets. Abbreviations: poor, statistically poor survival; good, statistically good survival; CIS, carcinoma in situ; Pap, papillary; (+), statistically significant positive association between pathway and given subtype; (−), statistically significant negative association between pathway and given subtype.